Immatics (IMTX) Stock Forecast & Price Target

$11.18

-0.23 (-2.02%)

(As of 03:04 PM ET)

Immatics - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Buy

Based on 2 Analyst Ratings

Sell
0

Hold
0

Buy
2

Based on 2 Wall Street analysts who have issued ratings for Immatics in the last 12 months, the stock has a consensus rating of "Buy." Out of the 2 analysts, 2 have given a buy rating for IMTX.

Consensus Price Target

$16.00
43.11% Upside

According to the 2 analysts' twelve-month price targets for Immatics, the average price target is $16.00. The highest price target for IMTX is $16.00, while the lowest price target for IMTX is $16.00. The average price target represents a forecasted upside of 43.11% from the current price of $11.18.

Get the Latest News and Ratings for IMTX and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Immatics and its competitors.

IMTX Analyst Ratings Over Time

Type	Current Forecast 10/2/23 to 10/1/24	1 Month Ago 9/2/23 to 9/1/24	3 Months Ago 7/4/23 to 7/3/24	1 Year Ago 10/2/22 to 10/2/23
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	2 Buy rating(s)	2 Buy rating(s)	2 Buy rating(s)	3 Buy rating(s)
Hold	0 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$16.00	$16.00	$16.00	$17.67
Forecasted Upside	43.11% Upside	44.27% Upside	35.36% Upside	63.73% Upside
Consensus Rating	Buy	Buy	Buy	Buy

Next Week Elon Could Trigger a Boom in this Sub-$3 Stock (Ad)

Next week, you’ll have a chance to get in on the ground floor of what could be Elon’s next big thing. You see, he’s set to reveal his new AI product that I believe will shock the world…

Click here to see the details and save your seat.

IMTX Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

IMTX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Immatics Stock vs. The Competition

Type	Immatics	Medical Companies	S&P 500
Consensus Rating Score	3.00	2.78	2.50
Consensus Rating	Buy	Moderate Buy	Hold
Predicted Upside	40.23% Upside	823.01% Upside	6.15% Upside
News Sentiment Rating	Positive News See Recent IMTX News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Action	Rating	Price Target	Upside/Downside on Report Date
9/5/2024	Cantor Fitzgerald 3 of 5 stars	Reiterated Rating	Overweight
5/16/2024	Mizuho 2 of 5 stars	Boost Target	Buy ➝ Buy	$14.00 ➝ $16.00	+44.40%
3/24/2023	Bryan, Garnier & Co 3 of 5 stars	Initiated Coverage	Buy	$16.00	+137.39%
3/23/2023	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Buy	$28.00 ➝ $25.00	+257.14%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 03:34 PM ET.

IMTX Forecast - Frequently Asked Questions

: According to the research reports of 2 Wall Street equities research analysts, the average twelve-month stock price forecast for Immatics is $16.00, with a high forecast of $16.00 and a low forecast of $16.00.
: 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Immatics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" IMTX shares.
: According to analysts, Immatics's stock has a predicted upside of 43.11% based on their 12-month stock forecasts.
: Immatics has been rated by research analysts at Cantor Fitzgerald in the past 90 days.
: Analysts like Immatics more than other "medical" companies. The consensus rating for Immatics is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how IMTX compares to other companies.

Stock Forecasts and Research Tools

Related Companies:

Today's Ratings:

Top Rated Stocks:

More Ratings Tools:

Next Week Elon Could Trigger a Boom in this Sub-$3 Stock (Ad)

Next week, you’ll have a chance to get in on the ground floor of what could be Elon’s next big thing. You see, he’s set to reveal his new AI product that I believe will shock the world…

Click here to see the details and save your seat.

This page (NASDAQ:IMTX) was last updated on 10/1/2024 by MarketBeat.com Staff

From Our Partners